The purpose of this study was to evaluate the incompatibility of ceftriaxone sodium with calcium-containing products using the ionic product of precipitation, and the measurement of insoluble microparticles using a light obscuration particle counter. Appropriate volumes of 2％ (w/v) calcium chloride solution were added to 0.4 2 mg/ml ceftriaxone isotonic sodium chloride solution, to make solutions with aˆnal calcium ion concentration of 1.25 mmol/l. The solutions were gently agitated and stored at 37°C for 24 h. The number of insoluble microparticles with a diameter less than 10 mm in the mixed sample solution, determined using a light obscuration particle counter, was increased when the ceftriaxone concentration was 0.8 mg/ml. The Saturation Index (deˆned as the ratio of the ionic product to the solubility product constant) of the prepared mixed solution was 1.1. A white precipitate could be observed visually when the ceftriaxone concentration of the sample solution was 7 mg/ml; the Saturation Index of the solution was 9.7. The eŠect of the calcium source on incompatibility with ceftriaxone sodium was also evaluated. The numbers of insoluble microparticles in sample solutions made by adding calcium chloride to the sample were signiˆcantly higher than those made by adding calcium gluconate. These results suggest that ceftriaxone should not be co-administered with calciumcontaining products even if no precipitation is observed visually. There will still be insoluble microparticles caused by incompatibility in the sample solution when the Saturation Index of the solution is over 1.0.
INTRODUCTION
A varied amount (33 67％) of a ceftriaxone dose is excreted in the urine as unchanged drug, while the remainder is secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. After a 1 g intravenous dose of ceftriaxone, the average tissue concentrations determined 1 3 h after dosing were 581 mg/ml in the gallbladder bile, 788 mg/ ml in the common bile duct, 898 mg/ml in the cystic bile duct, 78.2 mg/ml in the gallbladder wall, and 62.1 mg/ml in the plasma, as described in a previous article. 1) In 2007, the US FDA issued a safety alert 2) on the interaction of ceftriaxone with calcium-containing products, due to a number of neonatal deaths caused by ceftriaxone-calcium precipitates in lungs and kidneys. Cases of biliary concretions or sludge have been reported as adverse events associated with the interaction of ceftriaxone with calcium-containing products; these events are mentioned in the package insert. It was recommended that ceftriaxone should not be mixed with calcium-containing products and not administered in the same or diŠerent infusion lines or sites in any patient within 48 h (given the long halflife of ceftriaxone). Symptomatic biliary sludge made of ceftriaxone has frequently been observed in children, 3 5) and abnormal gallbladder sonograms were demonstrated in 17.3％ of children receiving high doses of ceftriaxone to treat infection. 6) There is also a report in an adult without gall bladder in‰ammation. 7) According to a study of the interaction from the standpoint of solubility, 8) although the theoretical solubility product constant K'sp (deˆned as the maximum solubility) for ceftriaxone-calcium salt was 1.62 ×10 -6 mol 2 /l 2 , precipitates were observed at an ionic product, [ mol 2 /l 2 , more than 10-fold greater than K'sp, that is, the Saturation Index (deˆned as the ratio of the ionic product to K'sp) was 10. The area between K'sp and the observed ionic product at which precipitate forms, deˆnes the metastable zone for ceftriaxonecalcium salt solubility.
In this study, the incompatibility of ceftriaxone sodium for injection and calcium-containing products was evaluated from the viewpoint of solubility by measuring the number of insoluble microparticles using a light obscuration particle counter.
EXPERIMENTAL

Materials
Rocephinfor injection containing 1 g ceftriaxone (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), and 100 ml isotonic sodium chloride solution (Terumo Co., Ltd., Tokyo) were purchased for use in this study. As calcium-containing injections, 20 ml calcium chloride injection 2％ (Otsuka Pharmaceutical Co., Ltd., Tokyo) and Calcicol (Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan) were also purchased. Further, as calcium-containing solutions, 500 ml Solacet F, 500 ml Solulact , 700 ml Hicaliq -2 (Terumo Co., Ltd.), 1000 ml Neoparen  No.1, 1000 ml Neoparen  No.2, 500 ml B‰uid  (Otsuka Pharmaceutical Co., Ltd.), 500 ml Solitax -H, and 500 ml Bicarbon(Ajinomoto Pharma Co., Ltd., Tokyo) were also purchased.
Measurement of Insoluble Microparticles Using a Light Obscuration Particle Counter
The employed method was essentially the same as the`Insoluble Particulate Matter Test for Injection Method 1. Light Obscuration Particle Count Test' described in the 15th edition of the Japanese Pharmacopoeia (2006). 9) All procedures were carried out at a clean bench. The number and size of microparticles were determined using a light obscuration particle counter KL 04 (RION Co., Ltd.). The thresholds of microparticle size were 1.3, 2.0, 5.0, 10.0, 20.0, 25.0, 40.0, 50.0, and 100.0 mm. The volume of each sample was 5 ml, and the mean value of three sample measurements was calculated. All instruments were washed with water after sample injection to eliminate insoluble microparticles derived from the devices.
The results of the incompatibility of ceftriaxone sodium for injection with calcium-containing solutions were evaluated according to the criteria for the maximum allowable number of insoluble microparticles in the 15th edition of the Japanese Pharmacopoeia. For injection preparations administered at a volume over 100 ml, the tolerated number of insoluble microparticles with a diameter 10 mm or greater is 25 or less, while that of microparticles with a diameter 25 mm or greater is 3 or less, per ml. ] exceeded K'sp for ceftriaxone-calcium salt. Appropriate volumes of 2％ (w/v) calcium chloride solution were added to 0, 0.4, 0.8, 1.2, 1.6, or 2 mg/ml ceftriaxone isotonic sodium chloride solution, to make solutions with aˆnal calcium ion concentration of 1.25 mmol/l. The solutions were gently agitated and stored at 37°C for 24 h, at which point the reaction of ceftriaxone and calcium had reached a state of equilibrium. The numbers of insoluble microparticles were measured 24 h after sample preparation, according to the method described in the previous section.
Calculation of Concentration of Ceftriaxone Ion
Judgment of Precipitation by Visual Observation
Appropriate volumes of 2％ (w/v) calcium chloride solution were added to 1, 3, 5, 7, 8 and 10 mg/ml ceftriaxone isotonic sodium chloride solution, to make solutions with aˆnal calcium ion concentration of 1.25 mmol/l. The solutions were gently agitated and stored at 37°C for 24 h. The mixtures were observed visually 24 h after sample preparation.
Identiˆcation of Precipitate Caused by Incompatibility
Appropriate volumes of 2％ (w/v) calcium chloride solution were added to 10 mg/ml The number of insoluble microparticles with a diameter less than 10 mm (n＝3±S.D.) formed when 2％ (w/v) calcium chloride solution was added to ceftriaxone injection (0.4 2 mg/ml) made with isotonic sodium chloride solution, and stored at 37°C for 24 h. Dunnet test;  p＜0.05;  p＜0.01.
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No. 1 ceftriaxone isotonic sodium chloride solution, to make solutions with aˆnal calcium ion concentration of 2.5 mmol/l. The solutions were gently agitated and stored at 25°C for 6 h. The elementary analysis of samples was done afterˆltration and drying under reduced pressure by an Instrument for Organic Elemental Micro Analysis (Chncorder MT-3, Yanagimoto Mfg Co., Ltd.).
Incompatibility of Ceftriaxone with Calcium Chloride and Calcium Gluconate Solutions
Measurement of Insoluble Microparticles Appropriate volumes of 2％ (w/v) calcium chloride solution or 8.5％ (w/v) calcium gluconate solution were added to 10 mg/ml ceftriaxone isotonic sodium chloride solution, to make solutions with aˆnal calcium ion concentration of 0.5, 1, 1.5, 2 and 2.5 mmol/ l. The solutions were gently agitated and stored at 20°C
, 25°C or 30°C. The numbers of insoluble microparticles were measured according to the method described previously, both immediately after mixing and 3 and 6 h later.
Judgment of Precipitation by Visual Observation
Appropriate volumes of 2％ (w/v) calcium chloride solution or 8.5％ (w/v) calcium gluconate solution were added to 10 mg/ml ceftriaxone isotonic sodium chloride solution, to make solutions with aˆnal calcium ion concentration of 2.5 mmol/l. The solutions were gently agitated and stored at 20°C, 25°C or 30°C for 6 h. The mixtures were observed visually and by stereomicroscope (SZX10, Olympus Co., Ltd.).
Measurement of Precipitate Weight
Appropriate volumes of 2％ (w/v) calcium chloride solution or 8.5％ (w/v) calcium gluconate solution were added to 10 ml of 10 mg/ml ceftriaxone isotonic sodium chloride solution, and theˆnal calcium ion concentrations adjusted to 1.5, 2, or 2.5 mmol/l. The solutions were gently agitated and stored at 25°C for 6 h. Samples were weighed afterˆltration and drying under reduced pressure.
Incompatibility of Ceftriaxone with Commercial Calcium-containing Products
Allen et al. 10) reported that the mixing of an intravenous ‰uid in an administration set with a secondary additive through a Y-injection site occurs in a 1:1 ratio. To simulate this inline mixing, 100 ml of calcium-containing solutions (B‰uid  , Bicarbon , Hicaliq -2, Neoparen  No.1, Neoparen  No.2, Solacet F, Solitax -H, and Solulact ) were added to 100 ml of 10 mg/ml ceftriaxone isotonic sodium chloride solution. The solutions were gently agitated and stored at 25°C for 6 h. The pH of each solution and the numbers of insoluble microparticles were measured according to the method described previously. The mixtures were also observed visually.
Statistical Analysis
The numbers of insoluble microparticles represent the mean of three values, plus or minus the standard deviation. The data on ionic products and K'sp were analyzed by one-way ANOVA with the Dunnet test. The data on incompatibility of ceftriaxone with calcium chloride or calcium gluconate were analyzed by two-way repeated ANOVA followed by Tukey's HSD test; statistical signiˆcance was accepted at the p＜0.05 or p＜0.01 level.
RESULTS AND DISCUSSION
Prediction of Incompatibility Using Saturation Index
The number of insoluble microparticles increased with increasing ceftriaxone concentration. In particular, the insoluble microparticles with a diameter less than 10 mm increased signiˆcantly in number when the ceftriaxone concentration of the sample solution was 0.8 mg/ml or higher (Fig. 1) ] exceeded K'sp for ceftriaxone-calcium salt. Some insoluble microparticles were observed even in 0 and/or 0.4 mg/ml ceftriaxone isotonic sodium chloride solution. This would conˆrm the previously reportedˆndings of such microparticles in the isotonic sodium chloride solution. 11) Figure 2 shows the results of visual observation. Precipitation was observed visually when the ceftriaxone concentration of the sample solution was 7 mg/ml or higher, and [Ca 2＋ ]×[C 18 H 15 N 8 O 7 S 3-3 ] was 1.56×10 -5 mol 2 /l 2 , which was 9.7-fold greater than K'sp, that is, the Saturation Index was 9.7. Precipitation under conditions in which the Saturation Index between 1 and 10 was not evaluated in the previous article. 8) The average concentration of ceftriaxone determined 1 3 h after dosing, was 898 mg/ml in the cystic bile duct after intravenous administration of 1 g of ceftriaxone, 1) mol 2 /l 2 , which was 1.2-fold greater than K'sp for ceftriaxone-calcium salt when the calcium ion concentration in the plasma was assumed to be 1.25 mmol/l. In our study, an increase of microparticles caused by incompatibility of ceftriaxone with calcium was conˆrmed at 1.79×10 -6 mol 2 /l 2 , which was 1.1-fold greater than K'sp for ceftriaxone-calcium salt in vitro. This suggests that biliary concretions or sludge are associated with the interaction of ceftriaxone with calcium-containing products.
Around 9 g of ionized calcium in the plasma iŝ ltered from the glomerulus 12) and 33 67％ of a ceftriaxone dose is excreted in the urine as unchanged drug. 1) We could not ignore the possibility of the precipitation of ceftriaxone with plasma calcium ion in the kidney, even if ceftriaxone was not administered simultaneously with calcium-containing products. This would correspond to the reason for the FDA Alert about the death of newborn and premature infants of precipitation in the kidney.
Identiˆcation of Precipitate Caused by Incompatibility
According to the elementary analysis, it was concluded that the precipitate consisted of ceftriaxone and calcium molecules at a ratio of 1:1, as described in previous reports. 8, 13) The chemical formula of precipitate predicted from its composition was C 18 H 16 N 8 O 7 S 3 Ca.
Incompatibility of Ceftriaxone with Calcium Chloride or Calcium Gluconate Figure 3 shows the number of insoluble microparticles in the sample solution made from 2％ (w/v) calcium chloride solution after 6 h storage. Figure 4 shows the number of insoluble microparticles in the sample solution made with 8.5％ (w/v) calcium gluconate solution after 6 h storage.
In the case of 2％ (w/v) calcium chloride solution, the number of insoluble microparticles immediately after sample preparation was under the permissible limit in all samples. Their number increased on storage, and by 3 h after sample preparation exceeded the permissible range at all temperatures when the sample solution contained 1 mmol/l calcium ion. At 6 h after sample preparation the number of insoluble microparticles exceeded the permissible range in a few samples when the sample solutions contained  0.5 mmol/l calcium ion. The microparticles were fewer at higher temperatures, 6 h after sample preparation.
In the case of 8.5％ (w/v) calcium gluconate solution, the number of insoluble microparticles exceeded the permissible range at all temperatures when the sample solution contained 1 mmol/l calcium ion by 3 h after sample preparation, similar to the sample with added calcium chloride. At 6 h after sample preparation, the number of insoluble microparticles exceeded the permissible range in samples stored at 30°C only when the sample solutions contained 0.5 mmol/l calcium ion. In samples stored at 20°C or 25°C the number of insoluble microparticles increased on storage and exceeded the permissible range when the sample solution contained 1 mmol/l calcium The number of insoluble microparticles with a diameter of 10 mm (A) and 25 mm (B) (n＝3±S.D.) formed when 8.5％ (w/v) calcium gluconate solution was added to ceftriaxone injection (10 mg/ml) made with isotonic sodium chloride solution, and stored at 20°C (◇), 25°C (□) and 30°C (△) for 6 h. Tukey's HSD test;  p＜0.05;  p＜0.01.
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No. 1 ion. There were no signiˆcant diŠerences in the number of insoluble microparticles at diŠerent temperatures.
In the sample solutions containing calcium chloride, the numbers of insoluble microparticles were signiˆcantly higher than those in the solutions containing calcium gluconate at all temperatures. Insoluble particles with a diameter of 10 mm and 25 mm numbered p＜0.01 in all solutions except those stored at 25°C for 3 h, which numbered p＜0.05. The results of the measurement of sample solutions stored at 25°C are shown in Fig. 5 .
On visual observation, the surface of the precipitate formed when 2％ (w/v) calcium chloride solution was added to 10 mg/ml ceftriaxone isotonic sodium chloride solution was rough; in contrast, in the solution to which 8.5％ (w/v) calcium gluconate solution was added, the surface was smooth. Under the stereomicroscope, the precipitate in the latter solution was greater than that in the former solution (Fig. 6) .
The weight of the precipitate in the solution when 2 ％ (w/v) calcium chloride solution was added to ceftriaxone isotonic sodium chloride solution, was signiˆcantly larger than that when 8.5％ (w/v) calcium gluconate solution was added, as shown in Fig. 7 .
In an examination of the incompatibility of calcium with phosphate, Henry et al. 14) reported that calcium chloride and calcium gluconate have diŠerent dissociation characteristics. A greater concentration of calci- um gluconate can be mixed with sodium phosphate than is possible for calcium chloride, because the degree of dissociation of calcium gluconate decreases as concentration increases. In other words, when the calcium concentrations were the same, precipitates were formed more easily by ceftriaxone with calcium chloride than with calcium gluconate. It is suggested that the diŠerence is due to the number of insoluble microparticles formed and weight of the precipitate.
Incompatibility of Ceftriaxone with Commercial
Calcium-containing Product Solutions Table 1 shows the calcium source and concentration of eight kinds of calcium-containing solutions used in the experiment. Table 2 shows the number of insoluble microparticles in the solutions that mixed 10 mg/ml ceftriaxone isotonic sodium chloride solution with calcium-containing solutions. The number of insoluble microparticles in all samples was within the per- The weight of the precipitate (n＝3±S.D.) for each sample to which 2 ％ (w/v) calcium chloride solution (■) or 8.5％ (w/v) calcium gluconate solution (□) was added to ceftriaxone injection (10 mg/ml) made with isotonic sodium chloride solution, and stored at 25°C for 6 h after sample preparation. Tukey's HSD test;  p＜0.05;  p＜0.01. The number of insoluble microparticles with a diameter of 10 mm and 25 mm (n＝3±S.D.) formed when calcium-containing solutions were added to ceftriaxone injection (10 mg/ml) made with isotonic sodium chloride solution, and stored at 25°C for 3 or 6 h. microparticles is believed to be less than that predicted using the Saturation Index, because the dissociation characteristics of the calcium from gluconate and from chloride are diŠerent.
Although the calcium ion concentrations in Solitax -H, Neoparen  No.2 and B‰uid  were the same, the number of insoluble microparticles was highest in Neoparen  No.2. The Saturation Index, calculated from the pH of the mixed solutions, was Hicaliq -2 (9.07) ＞B‰uid  (6.93) ＞Solitax -H (6.78) ＞Neoparen  No.2 (6.35) ＞Neoparen  No.1 (5.27) ＞Bicarbon(4.16) ＞Solacet F (4.15) ＞ Solulact(4.12). The number of insoluble microparticles in the mixed solutions did not follow this order. High concentrations of glucose in the calcium-containing solutions may also aŠect the calcium dissociation; further examination is therefore necessary.
In this study, the number of insoluble microparticles in all samples was within the permissible range, and no precipitation was observed visually. When the Saturation Index of the solution was 1.0, however, the number of insoluble microparticles increased due to the incompatibility of ceftriaxone with calcium, as shown by examination of the ionic product and K'sp. Therefore, when selecting ceftriaxone for the treatment of an infectious disease, co-administration with infusion solutions including calcium should be avoided. The possibility of causing a serious adverse event due to ceftriaxone-calcium complex formation in vivo, for example, by co-administration of multivitamins containing vitamin D or total parenteral nutrition containing high concentrations of calcium, or in conditions where the ionic calcium concentration in the plasma is increased (such as in the presence of malignant tumors), cannot be excluded, even if ceftriaxone is administered by another route.
CONCLUSION
These results suggested that ceftriaxone should not be co-administered with calcium-containing products, even if no precipitation is visible, because there may still be insoluble microparticles caused by incompatibility in solutions of Saturation Index ＞1. We cannot exclude the possibility of a serious adverse event arising, based on ceftriaxone-calcium complex formation in vivo, when ceftriaxone is co-administered with multivitamins including vitamin D, with total parenteral nutrition including high concentrations of calcium, and in conditions where the ionic calcium concentration in the plasma rises, even if ceftriaxone is administered by another route.
